免疫治疗是恶性肿瘤治疗的新方向,鼠源单克隆抗体用于人体可能会产生不良反应,而利用DNA重组技术、转基因技术和噬菌体展示技术制备的人源抗体可以克服这种缺陷,人源抗体已成为治疗性抗体的发展趋势。前列腺癌是男性较为常见的恶性肿瘤,目前治疗效果不能令人满意。针对前列腺特异性抗原、前列腺膜抗原和前列腺干细胞抗原等位点的治疗性抗体已经展开实验室和临床研究。利用抗体的导向作用对前列腺癌的靶向治疗,将有巨大的发展前景。 Immunotherapy is the new direction of the treatment of malignant tumors, murine monoclonal antibodies may cause adverse reactions in the human body, and the use of recombinant DNA technology, transgenic technology and phage display technology to prepare human antibodies can overcome this defect, human antibodies Has become a trend of development of therapeutic antibodies. Prostate cancer is a more common male malignant tumor, the current treatment effect is not satisfactory. Therapeutic antibodies to sites such as prostate-specific antigen, prostatic membrane antigen, and prostate stem cell antigen have been subjected to laboratory and clinical studies. Targeted treatment of prostate cancer using antibody-directed effects, there will be tremendous development prospects.